BRAF and colorectal carcinoma: Recently, it has been observed that patients with MSS BRAF V600E CRC with mutations in RNF43 (a negative regulator of the Wnt pathway) exhibit a better antitumoral response to BRAFi and/or EGFRi than those with RNF43 wild type: they have a longer PFS (HR 0.30; 95% CI 0.12–0.75) and overall survival (OS) (HR 0.26; 95% CI 0.10–0.71).